[1] WHO. Hepatitis B vaccines. Wkly Epidemiol Rec, 2009,84 : 405-420.
[2] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012 ,30:2212-2219.
[3] Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology,2007 ,45:1193-1198.
[4] Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol,2015 ,12:258-263.
[5] 刘娜,武琼,徐光华,等.慢性HBV携带状态自然转归的研究.肝脏,2016,21: 755-758.
[6] 吴殿磊,徐光华,吕社民,等. 胚胎期、新生儿和儿童期HBV感染后免疫耐受研究进展.细胞与分子免疫学杂志,2016,32:568-570.
[7] Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology, 2006 , 43: S173-S181.
[8] Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol, 2014,,20 : 10395-103404.
[9] 谢晶日,李婷婷,李明,等. 慢性乙型病毒性肝炎免疫耐受的研究进展. 中华中医药学刊,2014,32 :12-14.
[10] Dandri M,Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut,2012,61 Suppl 1:i6-17.
[11] Isogawa M, Tanaka Y.Immunobiology of hepatitis B virus infection. Hepatol Res, 2015 ,45: 179-189.
[12] Guidotti LG, Chisari FV.Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol, 2001,19:65-91.
[13] Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet, 2011,377:1198-1209.
[14] 涂燕云,甘龙禹,高鑫,等.慢性HBV感染免疫耐受期T淋巴细胞研究进展.中国肝脏病杂志(电子版),2016,8:22-25.
[15] Kollmann TR, Levy O, Montgomery RR, et al.Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity, 2012 ,37:771-783.
[16] Shaw AC, Joshi S, Greenwood H, et al.Aging of the innate immune system. Curr Opin Immunol, 2010, 22: 507-513.
[17] Bertoletti A, Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J, 2013 ,89:294-304.
[18] Henao-Mejia J, Elinav E, Jin C, et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 2012 , 482:179-185.
[19] Watashi K, Liang G, et al.Interleukin-1 and tumor necrosis factor-a trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem, 2013, 288: 31715-31727.
[20] Watashi K, Liang G, Iwamoto M, et al.Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem, 2013, 288:31715-31727.
[21] Saxena R, Kaur J.Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol, 2015,7:1572-1580.
[22] Sun HH, Zhou DF, Zhou JY.The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J Med Virol, 2016 ,88:13-20.
[23] Arima S, Akbar SM, Michitaka K, et al. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med,2003 ,11):169-174.
[24] Thimme R, Wieland S, Steiger C, et al.CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol,2003 ,77:68-76.
[25] Kollmann TR, Levy O, Montgomery RR, et al.Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity,2012,37:771-783.
[26] Yan H, Zhong G, Xu G, et al.Sodium taurocholate cotrans-porting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 2012,1:e00049.
[27] Zoulim F.New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol,2005,42:302-308.
[28] Sunbul M.Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol,2014,20:5427-5434.
[29] Liu F, Chen L, Yu DM, et al.Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut,2011,60:1269-1277.
[30] Fedson DS.Treating influenza with statins and other immuno-modulatory agents .Antiviral Res, 2013,99: 417-435.
[31] Maini MK, Peppa D.NK cells: a double-edged sword in chronic hepatitis B virusinfection. Front Immunol,2013,4:57. |
